Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 661 AL 675

Direct-To-Consumer Genetic Testing: Summary of a Workshop

National Research Council (US) and Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health.

Washington (DC): National Academies Press (US); 2010.

SPECT and PET in Atypical Parkinsonism

Seibyl JP.

PET Clin. 2010 Jan;5(1):65-74. doi: 10.1016/j.cpet.2010.02.005. Epub 2010 May 27.

(18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons

Hefti FF, Kung HF, Kilbourn MR, Carpenter AP, Clark CM, Skovronsky DM.

PET Clin. 2010 Jan;5(1):75-82. doi: 10.1016/j.cpet.2010.02.001. Epub 2010 May 27.

Neurotransmission in Parkinson's disease: beyond dopamine

Barone P.

Eur J Neurol. 2010 Mar;17(3):364-76. doi: 10.1111/j.1468-1331.2009.02900.x. Epub 2009 Dec 30.

Apraxia contributes to the motor deficit in Parkinson's Disease and multiple system atrophy

Swash M.

Eur J Neurol. 2010 Mar;17(3):346-7. doi: 10.1111/j.1468-1331.2009.02909.x. Epub 2009 Dec 30.

Dopamine influences primary motor cortex plasticity and dorsal premotor-to-motor connectivity in Parkinson's disease

Suppa A, Iezzi E, Conte A, Belvisi D, Marsili L, Modugno N, Fabbrini G, Berardelli A.

Cereb Cortex. 2010 Sep;20(9):2224-33. doi: 10.1093/cercor/bhp288. Epub 2010 Jan 5.

Ageing, neurodegeneration and Parkinson's disease

Hindle JV.

Age Ageing. 2010 Mar;39(2):156-61. doi: 10.1093/ageing/afp223. Epub 2010 Jan 5.

Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder

Ostrem JL, Christine CW, Glass GA, Schrock LE, Starr PA.

Stereotact Funct Neurosurg. 2010;88(1):51-5. doi: 10.1159/000268742. Epub 2009 Dec 24.

Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease

Surmeier DJ, Guzman JN, Sanchez-Padilla J.

Cell Calcium. 2010 Feb;47(2):175-82. doi: 10.1016/j.ceca.2009.12.003. Epub 2010 Jan 6.

Parkinson's disease and cancer risk: a systematic review and meta-analysis

Bajaj A, Driver JA, Schernhammer ES.

Cancer Causes Control. 2010 May;21(5):697-707. doi: 10.1007/s10552-009-9497-6. Epub 2010 Jan 7.

Metabotropic glutamate receptors: physiology, pharmacology, and disease

Niswender CM, Conn PJ.

Annu Rev Pharmacol Toxicol. 2010;50:295-322. doi: 10.1146/annurev.pharmtox.011008.145533.

Serum somatostatin in early-stage Parkinson's disease

Shiraishi M, Kobayashi T, Watanabe H, Kamo T, Hasegawa Y.

Acta Neurol Scand. 2010 Apr;121(4):225-9. doi: 10.1111/j.1600-0404.2009.01178.x. Epub 2010 Jan 3.

Optimized beamforming for simultaneous MEG and intracranial local field potential recordings in deep brain stimulation patients

Litvak V, Eusebio A, Jha A, Oostenveld R, Barnes GR, Penny WD, Zrinzo L, Hariz MI, Limousin P, Friston KJ, Brown P.

Neuroimage. 2010 May 1;50(4):1578-88. doi: 10.1016/j.neuroimage.2009.12.115. Epub 2010 Jan 4.

INPH and Parkinson disease: differentiation by levodopa response

Morishita T, Foote KD, Okun MS.

Nat Rev Neurol. 2010 Jan;6(1):52-6. doi: 10.1038/nrneurol.2009.195.

T1rho and T2rho MRI in the evaluation of Parkinson's disease

Nestrasil I, Michaeli S, Liimatainen T, Rydeen CE, Kotz CM, Nixon JP, Hanson T, Tuite PJ.

J Neurol. 2010 Jun;257(6):964-8. doi: 10.1007/s00415-009-5446-2. Epub 2010 Jan 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias